Expected Drop In COVID-19 Vaccine Sales Hits Beximco’s Bottom Line
Subsidiary Entities Collectively Profitable For First Time Following Synovia Acquisition
The absence of any income from distributing AstraZeneca’s COVID-19 vaccine led to Beximco’s pre-tax profit dropping by 13% in the first six months of its financial year ending in June 2023. However, profits after tax actually rose slightly when discounting last year’s COVID-19 vaccine impact.
You may also be interested in...
Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.